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Abstract We developed a stable expression system for con- 
formationally intact recombinant human PR3 (rPR3) using the 
human mast cell line HMC-I. Like in U937 cells, the rPR3 is 
processed from a 34 kDa precursor to the 29 kDa mature form, 
primarily as the result of oligosaccharide trimming. The rPR3 
binds [3H]DFP and hydrolyzes the snbstrate N-methoxysuccinyl- 
Ala-Ala-Pro-Val-pNA. The enzymatic activity is inhibited by 
greater than 95% by al-PI.  The rPR3 and the enzymatically 
inactive mutant rPR3-S176A are both packaged in granules. 
Thus, proteolytic autoprocessing is not required for PRYs 
targeting to granules. This rPR3 is the first to be recognized 
by most c-ANCA from WG patients and all anti-PR3 ANCA 
that were detected by standard anti-PR3 specific ELISA. This 
expression system for rPR3 represents a versatile tool for the 
analysis of its intraceHular processing, structure-function rela- 
tionships and interaction with autoantibodies. 
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I. Introduction 
emphysema [4,9] and Wegener's granulomatosis (WG) [10]. 
WG is a specific form of vasculitis associated with circulating 
anti-neutrophil cytoplasmic autoantibodies directed against 
PR3 (c-ANCA) [3]. The interaction of c-ANCA with PR3 
exposed on the surface of cytokine stimulated neutrophils is 
felt to be significant for the pathogenesis of the disease [10]. 
The expression of recombinant PR3 (rPR3) as a fusion 
protein in E. coli and in baculovirus systems failed to generate 
an enzymatically active recombinant product that is recog- 
nized by the majority of c-ANCA sera [11-13]. Thereby, these 
reports have confirmed that most c-ANCA recognize confor- 
mational epitopes of PR3. The final conformation of PR3 is 
determined by its disulfide bonds, appropriate glycosylation, 
as well as only partially understood specific intracellular pro- 
cessing events, of which most eukaryotic expression systems 
may not be capable. 
Here we present a stable expression system for rPR3 using 
the human mast cell line (HMC-1). The expressed rPR3 is 
enzymatically active and recognized by c-ANCA sera, suggest- 
ing that the recombinant product is conformationally intact. 
In HMC-1 cells, rPR3 is processed like endogenous PR3 in 
U937 cells, and targeted to granules. 
The neutrophil azurophil granule constituent proteinase 3
(PR3; EC 3.4.21.76) is a neutral serine protease with substan- 
tial amino acid sequence homology with elastase, cathepsin G
and azurocidin [1-3]. PR3 has enzymatic activity for elastin, 
fibronectin and the basement membrane proteins collagen 
type IV and laminin [4]. Since activated neutrophils express 
PR3 on their surface [5], it could facilitate their migration 
through basement membranes. PR3 may be instrumental in 
host defense and regulation of proliferation and differentation 
of hematopoetic cells [2,6]. PR3 can also proteolytically pro- 
cess interleukin 8 into a chemotactically more potent form [7], 
and cleave the mammalian heat shock protein hsp28 [8]. These 
two properties clearly distinguish PR3 functionally from elas- 
tase. 
PR3 has been implicated in the pathogenesis of pulmonary 
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2. Materials and methods 
2.1. Materials 
Unless specified otherwise, all materials were from Sigma, St. Louis, 
MO. The following anti-PR3 antibodies were used: the monoclonal 
antibody (moAB) WGM2, kindly provided by Dr. E. Csernok [14]; 
the moABs 4A3, 4A5, 6A6, and the polyclonal rabbit anti-PR3 anti- 
serum, kind gifts from Dr. J. Wieslander [15,16]. MoABs specific for 
human mast cell tryptase (Dako, Carpinteria, CA), and rabbit poly- 
clonal antibodies against human mast cell chymase (Biogenesis, Bour- 
nemouth, UK), human neutrophil elastase, myeloperoxidase (both 
from Dako, Carpinteria, CA), and cathepsin G (Cortex Biochem., 
San Leandro, CA) were also used. 
2.2. Cell culture, DNA constructs, and transfection 
Promyelomonocytic U937 cells obtained from the American Type 
Culture Collection (Bethesda, MD) were cultured according to their 
instructions. The human mast cell line HMC-1, a kind gift from Dr. J. 
H. Butterfield, was cultured as described [17]. Some transfected HMC- 
1 cells were subsequently cultured in RPMI/10% BCS. 
U937 cell mRNA served as template for the preparation of PR3 
cDNA. The following primers were prepared (mutations underlined): 
1,5'-GCCCCCCAGCCCTGCCCTGGCGTCCGTG-3 ~ 
2,5'-CGGCCAGCGCTGTGGGAGGGGCGGTTCA-3' 
3,5'-GTCAAAGCTTCCCACCATGGCTCACCGGCCCCCC- 
AGCCCTG-3 ~ 
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4,5 ' -GTACTCTAGACGGCCAGCGCTGTGGGAG-3 ~ 
5, 5' - ATCTGCTTCGGAGACGCCGGTGGCCCCCTGATC - 3' 
and 
6, 5' - GATCAGGGGGCCACCGGCGTCTCCGAAGCAGAT - 3'. 
Reverse transcription of mRNA from U937 cells was followed by 
amplification by polymerase chain reaction (PCR) using primers 1 
and 2, resulting in a cDNA fragment spanning from nucleotide posi- 
tions 9 to 790 of the published sequence [18]. HindIII and XbaI re- 
striction sites were added to the 5' and 3' ends, respectively, by PCR 
using primers 3 and 4. This insert was cloned into the HindlII/XbaI 
restricted expression vector pRcCMV (InVitrogen, San Diego, CA), 
resulting in the plasmid pRcCMWPR3. 
The plasmid pRcCMV/PR3-S176A was prepared to express the 
enzymatically inactive mutant rPR3-S 176A using the splicing by over- 
lap extension method [19]. Overlapping DNA fragments generated by 
PCR with primers 5 and 4, and primers 6 and 3 were spliced together 
and cloned into the vector pRcCMV. 
The plasmids were transfected into HMC-1 cells by electroporation 
[20]. An rPR3 expressing cell population (HMC-1/PR3) was selected 
using G418 (genticin, Gibco, Grand Island, NY). Cells growing in the 
presence of G418 (600 ~tg/ml) were subjected to cloning by dilution 
selection. Control cells (HMC-1/VEC) were mock-transfected with the 
plasmid pRcCMV without insert, selected and cultured under the 
same conditions. 
2.3. Immunofluorescence, biosynthetic labeling and immunoprecipitation 
Ethanol-fixed cytospin preparations of human peripheral blood 
neutrophils, HMC-1, HMC-1NEC, HMC-1/PR3 and HMC-1/PR3- 
S176A cells were prepared and indirect immunofluorescence (IIF) 
was performed as described elsewhere [21]. 
Biosynthetic labeling and immunoprecipitation were performed 
using the following modification of a protocol described elsewhere 
[22]. 2× 107 U937, HMC-1NEC or HMC-1/PR3 cells were washed 
twice in methionine- and cysteine-free RPMI (Gibco, Gaithersburg, 
MD) containing 10% BCS, and incubated overnight in methionine- 
and cysteine-free RPMI/10% BCS to which 100 ~Ci/ml of 
[35S]methionine/[35S]cysteine (ICN, Costa Mesa, CA) had been added. 
Cells were then washed, lysed, sonicated, normalized for trichloro- 
acetic acid-precipitable counts, precleared with Staphylococcus aureus 
(Gibco, Gaithersburg, MD), and immunoprecipitated. The immuno- 
precipitates were washed three times in the radio-immunoprecipitation 
buffer, electrophoresed on 12% SDS-PAGE gels, and visualized by 
autoradiography. 
For pulse-chase xperiments, cells were washed, starved for 30 min 
in methionine- and cysteine-free RPMI/5% BCS, and incubated for 
30 min in the same media supplemented with 100 ~tCi/ml of 
[35S]methionine/[35S]cysteine (pulse labeling), washed once again, re- 
suspended, and cultured in RPMI/10% BCS for the various time per- 
iods (chase). For each time point 10x 106 cells were collected and 
analyzed. 
2.4. Deglycosylation of immunoprecipitates 
Immunoprecipitates of metabolically labeled cells were prepared, 
washed, resuspended in 10 ~tl of 0.5% SDS, and incubated for 2 min 
at 95°C. After addition of 90 ~1 of digestion buffer (20 mM Na2HPO4, 
10 mM NAN3, 50 mM EDTA, 0.5% (v/v) Nonidet P-40, pH 7.2), the 
sample was divided in two. One sample served as the control; 0.4 U 
N-glycosidase F (Boehringer, Mannheim, Germany) was added to the 
second sample, and both were incubated at 37°C for 15 h. The sam- 
ples were then precipitated in 30% trichloroacetic a id, washed in cold 
acetone and analyzed by SDS-PAGE and autoradiography. 
2.5. [3H]Diisopropylfiuorophosphate l b ling 
20 × 106 cells were lysed in 500 ktl of 1% Triton X-100, 20 mM Tris, 
pH 6.8 and sonicated. Serine proteases were labeled by incubating the 
cell lysate with [3H]diisopropylfluorophosphate (DFP) (1 pCi/~tl at a 
specific activity of 8.4 Ci/mmol; DuPont NEN, Wilmington, DE) for 
15 min at 4°C. The cell lysate was precleared with S. aureus prior to 
immunoprecipitation and analysis by SDS-PAGE and autoradiogra- 
phy. 
2.6. Enzymatic activity assay 
5×105 cells suspended in 20 mM Tris, 0.5 M NaC1, pH 7.5 each 
were placed in microtiter wells, centrifuged at 900 ×g, and fixed in 
95% ethanol at 4°C. Substrates were dissolved at concentrations of 10 
mM in DMSO, and diluted to 2 mM in 0.1 M Tris, pH 8.1. Plated 
cells were treated with 50 p.1 of 1% Triton X-100 in 0.1 M Tris, pH 8.1 
for 30 min at 37°C. 50 /al of substrate solution were added to the 
wells, incubated at 37°C, and the hydrolysis of the substrate was 
detected colorimetrically. Data are expressed as absorbance of p-ni- 
troanaline at 405 nm minus absorbance at 490 nm. Inhibitors, when 
used, were added during the first 30 min incubation. 
3. Results and discussion 
3.1. Phenotype of  HMC-1 cells 
The phenotype of the HMC-1 cells used was determined by 
I IF using antibodies against PR3, elastase, cathepsin G, mye- 
loperoxidase, mast cell chymase and tryptase. HMC-1 cells 
(70% of cells) expressed only mast cell tryptase. The tryptase 
expression is consistent with a report by Nilsson, but in con- 
trast to the original description of the HMC-1 cell line [17,23]. 
We could not confirm Nilsson's observation of 5% of HMC-1 
cells expressing cathepsin G. This could be the result of dif- 
ferent antibodies used. However, previously reported discrep- 
ancies in the phenotype of HMC-1 cells have been attributed 
to secondary alterations occurring during prolonged passage 
in vitro [17,23]. 
3.2. Expression of rPR3 in HMC-1 cells 
Sequence verification of the expression vector pRcCMV/ 
PR3 confirmed that the amino acid residue Arg-228 was miss- 
ing from the originally published sequence [18,24]. Expression 
of PR3 mRNA of the expected size (0.9 kb) in HMC-1/PR3 
cells was detected by Northern blot analysis (performed as 
described elsewhere [25]), but not in HMC-1/VEC or non- 
transfected HMC-1 parent cells (not shown). 
To determine whether HMC-1/PR3 cells expressed rPR3 
protein, I IF was performed on ethanol-fixed cytospin prepara- 
tions. A strong granular cytoplasmic fluorescence signal was 
detected in HMC-1/PR3 cells with all anti-PR3 antibodies 
including the conformation sensitive WGM2 and c-ANCA 
(Fig. 1B,E). No signal was detected in non-transfected 
HMC-1 or HMC-1NEC control cells with either of the anti- 
bodies (Fig. IF), or when non-immune control antibodies 
were used on HMC-1/PR3 cells (Fig. 1D). Confocal micro- 
scopy confirmed that rPR3 is stored in granules in HMC-1/  
PR3 cells (Fig. 1C). The active site mutant rPR3-S176A also 
was recognized by all anti-PR3 antibodies and appeared to be 
deposited in granules (not shown). 
Immunoprecipitation experiments (Fig. 2A) showed that all 
specific anti-PR3 antibodies, with the exception of WGM2, 
specifically immunoprecipitated rPR3 from extracts of 
HMC-1/PR3 cells, but not of HMC-1NEC cells. Normal 
mouse IgG, normal rabbit and human sera served as non- 
immune controls. The most prominent specific immunoprecip- 
irate from HMC-1/PR3 cells had an apparent molecular mass 
of 29 to 34 kDa, consistent with that of native neutrophil and 
U937 cell PR3 [9,26]. 
Two additional protein species of about 47 and 83 kDa 
were co-immunoprecipitated by the PR3 specific antibodies 
from HMC-1/PR3, but not HMC-1NEC cells. These were 
also immunoprecipitated from U937 cells which endogenously 
produce PR3 (Fig. 2B). The existence of these previously not 
characterized larger proteins was originally shown by Gold- 
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Fig. 1. Indirect immunofluorescence of stably transfected HMC-1 cells. (A) Phase contrast view of HMC-1/PR3 cells; (B) staining of rPR3 with 
the conformation-sensitive moAB WGM2. (C) Confocal micrograph of HMC-1/PR3 cells stained with the polyclonal rabbit antiserum shows 
rPR3 deposited in HMC-1 cell granules. (D) HMC-1/PR3 cells incubated with normal human control serum, (E) and c-ANCA serum. (F) c- 
ANCA serum incubated on HMC-1NEC cells. 
schmeding et al. [27] in immunoprecipitates obtained with c- 
ANCA patient sera from neutrophil granule extracts. The 
nature of the 47 and 83 kDa proteins remains unknown. It 
is unlikely that they represent multimers of PR3 since the gels 
were run under reducing conditions. The possibility that they 
represent related protein products from different genes has 
been excluded by the control experiments. The fact that these 
proteins do not bind [3H]DFP could indicate that they repre- 
sent inhibitor or chaperoning molecules that are bound to 
PR3 intracellularly. 
3.3. Intracellular processing of rPR3 
The sequence homologies and structural similarities be- 
tween PR3, elastase and cathepsin G make it likely that these 
enzymes are all processed in a similar fashion [18,28]. Elastase 
and cathepsin G have been shown to be processed to the 
mature enzymatically active enzyme by cleavage of an N- 
terminal activation dipeptide [29]. Also, there is evidence for 
cleavage of a C-terminal propeptide of cathepsin G [29]. A 
most recent report suggests that PR3 is indeed processed in a 
similar fashion in U937 cells [26]. To investigate he suitability 
of our recombinant system for studies of intracellular proces- 
sing of PR3, we evaluated the fate of pulse labeled rPR3 in 
HMC-1/PR3 cells, and compared it to that of endogenous 
PR3 in U937 cells. The data indicate that PR3 is processed 
from a 34 kDa precursor to the 29 kDa form in both HMC-1/ 
PR3 and U937 cells (Fig. 3A). The process appears to be 
completed after 6 h in HMC-1/PR3 cells, and after 3 h in 
U937 cells. Some unprocessed 34 kDa precursor is secreted 
into the media. The observed rop in molecular size is too 
large to be explained by the proteolytic processing of the 
protein core, which would account for a molecular mass re- 
duction of about 1 kDa. The observed reduction in molecular 
mass is more likely a consequence of sugar side chain trim- 
ming, as has been reported for U937 cells [26] 
The cDNA sequence of PR3 indicates two potential N- 
linked glycosylation sites [18,24]. Native PR3 immunoprecipi- 
tated from neutrophil azurophil granule extracts howed an 
increased electrophoretic mobility in SDS after digestion with 
N-glycosidase F [27], suggesting that native neutrophil PR3 is 
indeed glycosylated. The observed rop in molecular mass 
after N-glycosidase F treatment (Fig. 3B) indicates that the 
processing of rPR3 from a 34 kDa to a 29 kDa form is indeed 
largely the result of the processing of N-linked glycans. De- 
glycosylation of immunoprecipitates of total HMC-1/PR3 
cells lysates results in a double band on SDS-PAGE (Fig. 
3B), whereas deglycosylation f single time points from the 
pulse-chase experiments results in a single band (not shown). 
268 
2 3 4 5 6 7 8 
U. Specks et al./FEBS Letters 390 (1996) 265-270 
1 2 
0 0 
A B 
Fig. 2. Immunoprecipitation f [35S]methionine/[35S]cysteine-labeled cell xtracts. (A) Cell lysates of HMC-1/PR3 cells (lanes 1,3,5,7) and of 
HMC-1NEC cells (lanes 2,4,6,8) were immunoprecipitated with the polyclonal rabbit anti-PR3 serum (lanes 1,2), non-immune rabbit control 
serum (lanes 3,4), the moAB 4A3 (lanes 5,6) and non-immune mouse IgG (lanes 7,8). The 29-34, 47 and 83 kDa proteins pecifically immuno- 
precipitated from HMC-1/PR3 cells are indicated by arrows. (B) Immunoprecipitation of endogenous PR3 from U937 cells with the moAB 
4A3 (lane 1) and non-immune control mouse IgG (lane 2) confirms the presence of the 47 and 83 kDa protein species in U937 cells. Autora- 
diography exposure times were 8 h (A) and 21 days (B). 
This indicates that proteolytic leavage of a 1 kDa propeptide 
of the peptide core of rPR3 occurs which is consistent with 
appropriate proteolytic processing of the C-terminus. 
The enzymatically inactive mutant rPR3-S 176A is processed 
and targeted to granules like the wild-type rPR3, indicating 
that proteolytic autoprocessing is not required, and that the 
processing of rPR3 is determined by the presence of the pro- 
cessing machinery in the host cell. The HMC-1/PR3 cell sys- 
tem is particularly useful for the study of intracellular proces- 
sing events, because it allows the application of in vitro 
mutagenesis, and because of the high rPR3 expression result- 
ing in immunoprecipitation signals being detectable after 24- 
72 h, compared to 21-28 days for U937 cells. 
3.4. Enzymatic activity of rPR3 
One of the enzymatic haracteristics of serine proteases i
their ability to bind the serine protease inhibitor DFP. 
[3H]DFP bound to rPR3 of 29-34 kDa size (Fig. 4A), but 
not to the 47 and 83 kDa PR3-related proteins, confirming 
that only the 29-34 kDa rPR3 contains an active site serine. 
As expected, the rPR3-S176A mutant was unable to bind 
[3H]DFP (Fig. 4A). 
PR3 preferentially cleaves substrates with small aliphatic 
amino acids at the P1 site, and N-methoxysuccinyl-Ala-Ala- 
Pro-Val-pNA represents its most specific synthetic substrate 
[4]. This was hydrolyzed by lysates of HMC-1/PR3, but not 
HMC-1NEC or HMC-1/PR3-S176A cells (Fig. 4B). 
The activity of rPR3 against his substrate was inhibited by 
greater than 95% in the presence of 1 mM DFP or 1.85 gM 
al-PI ,  its major natural inhibitor (Fig. 4B). No inhibition was 
observed in the presence of 0.1 TIU/ml aprotinin, 1 mM N- 
ethylmaleimide or 35 laM Dansyl-Glu-Gly-Arg-chloromethyl 
ketone which inhibits enzymes with specificity for basic amino 
acids at the P1 site, such as tryptase (not shown). 20% inhibi- 
tion was observed in the presence of 1.2 I.tM recombinant 
eglin C (not shown). No hydrolysis of the substrate succi- 
nyl-Ala-Ala-Ala-pNA was observed by HMC-1/PR3, HMC- 
1/VEC or HMC-1/PR3-S176 A cells under these assay condi- 
tions (not shown). Together, these findings indicate that rPR3 
recognizes high and low molecular weight substrates and that 
the substrate and inhibitor spectrum is consistent with what 
has been reported for native PR3 purified from neutrophils 
[4]. 
To estimate the amount of rPR3 expressed by HMC-1/PR3 
cells, we compared the HMC-1/PR3 cell activity against N- 
methoxysuccinyl-Ala-Ala-Pro-Val-pNA with that of neutro- 
phils in this assay. Since neutrophils contain enzymes other 
than PR3 that have activity against this substrate, such as 
elastase, and since PR3 is not inhibited by aprotinin, neutro- 
phil lysates were assayed in the presence of 0.1 TIU/ml apro- 
Table 1 
Diagnoses and anti-PR 3 assay results of 40 c-ANCA positive patients 
n = positive on 
PMNcytospins HMC-1/PR3 cytospins Anti-PR3 ELISA 
Wegener's granulomatosis 29 18 12 
Microscopic polyangiitis 8 6 6 
Ulcerative colitis 1 1 1 
Sclerosing cholangitis 1 0 0 
Somatoforme pain syndrome l 0 0 
Total 40 25 19 
U. Specks et al./FEBS Letters 390 (1996) 265-270 
Cell  Lysate 
HMC-1 /PR3 
Media  
1 
I 
+ 
0.5 1.5 3 6 24 0.5 1.5 3 
m 
m 
RD 
83 
45 
32 
269 
U937 - -  32  
A NI 0.5 1.5 3 6 24 0.5 1.5 3 B 
Fig. 3. (A) Pulse-chase experiments indicate intracellular processing from a 34 kDa rPR3 precursor to a 29 kDa rPR3 form in HMC-1/PR3 
and U937 cells. The unprocessed 34kDa form of rPR3 appears to be secreted into the cell media. The time intervals (h) of the chase are indi- 
cated at the bottom of the panels. 10x 106 cells per time point were lysed and immunoprecipitated using the rabbit polyclonal anti-PR3 anti- 
body. Autoradiography exposure times were 40 h for HMC-1/PR3 cell lysates and media, 21 days for U937 cell lysates and 5 days for U937 
cell media. (B) Digestion of rPR3 with N-glycosidase F. 20× 106 HMC-1/PR3 cells were metabolically labeled overnight and immunoprecipi- 
tated. The immunoprecipitate was divided into two equal aliquots, which were incubated with (+) or without (-) N-glycosidase F overnight 
under identical conditions, followed by SDS-PAGE (12% gel). Autoradiography exposure time was 40 h. 
tinin. The aprotinin-resistant activity of one neutrophil 
against his substrate is equivalent to that of two HMC-1/ 
PR3 cells. 
The enzymatic activity data also confirm that HMC-1 cells 
possess the intracellular armentarium required to appropri- 
ately process neutrophil serine proteases. As demonstrated 
for elastase, cathepsin G and lymphocyte granzymes, the 
cleavage of a two-amino-acid residue propeptide is required 
for PR3 to assume its conformation dependent enzymatic 
function [29,30]. Its cleavage is performed by dipeptidylpepti- 
dase I (DPPI) [31,32], which appears to be missing in non- 
hematopoetic eukaryotic ells [30,33]. In U937 cells the acti- 
vation dipeptide of PR3 appears to be cleaved by a cysteine 
protease distinct from DPPI, while elastase is activated by 
DPPI [26]. The fact that rPR3 is activated to a fully active 
enzyme in HMC-1 cells suggests that this unidentified proces- 
sing enzyme is also present in HMC-1 cells, or, alternatively, 
that rPR3 can also be activated by DPPI. 
3.5. Recognition of rPR3 by c-ANCA sera 
The most recent report of rPR3 expression i  a baculovirus 
system has confirmed that that the majority of c-ANCA rec- 
ognize conformational epitopes on PR3, and that insect cells 
are not able to process rPR3 into a conformationally intact 
form [13]. To determine whether PR3 expressed by HMC-1/ 
PR3 cells is recognized by c-ANCA, 40 consecutive serum 
samples that had previously been determined to be c-ANCA 
positive by standard IIF on neutrophil cytospin preparations 
[21] and control sera (5 normal, 5 anti-myeloperoxidase 
ANCA positive, 10 containing various patterns of ANA and 
5 containing anti-mitochondrial antibodies) were obtained 
from the clinical laboratory. The samples were tested inde- 
pendently by three investigators by IIF on cytospin prepara- 
tions of HMC-1/PR3 and HMC-1NEC cells, and in parallel 
for PR3-reactivity by commercial ELISA [34]. After comple- 
tion of the data collection the clinical records of the c-ANCA 
positive patients were reviewed to correlate their clinical diag- 
noses with the test results (Table 1). 
No cytoplasmic signal was detected when these 40 antisera 
were used on cytospin preparations of HMC-1NEC control 
cells (Fig. IF). Also, no specific signal was detectable when 
normal (Fig. 1D) or any of the other control sera were used. 
The data confirm that routine c-ANCA testing by IIF using 
neutrophil substrates may detect cytoplasmic fluorescence 
even in patients without any ANCA associated disease 
[10,15]. The two sera for which this was the case did not 
contain antibodies against PR3 as indicated by the test results 
using HMC-1/PR3 cells as substrate. The parallel use of 
mock-transfected control cells excludes false-positive results 
that could be caused by circulating antibodies directed against 
cytoplasmic antigens other than PR3 when neutrophils are 
used as test substrate [15]. 
A substantially higher number of anti-PR3 ANCA contain- 
ing sera were recognized by the HMC-1/PR3 cell assay than 
by the anti-PR3 ELISA. That not all true positive samples 
reported by the clinical laboratory were recognized on 
HMC-1/PR3 cells can be explained by the fact the standard 
IIF on neutrophils was performed on flesh serum samples, 
whereas the testing on HMC-1/PR3 cells and by ELISA was 
preformed later, after the samples had been frozen and 
thawed several times. However, it cannot be excluded that 
some patients with WG may have ANCA directed against 
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Fig. 4. Enzymatic activity of rPR3. (A) [3H]DFP labeling of rPR3. 
Only the rPR3 expressing HMC-1/PR3 cells (lane 3), but not the 
mock-transfected HMC-1/VEC (lane 1) or HMC-1/PR3-S176A cells 
(lane 2), contain DFP-binding PR3. Autoradiography exposure time 
was 4 days. (B) Hydrolysis of the substrate N-methoxysuccinyl-Ala- 
Ala-Pro-Val-pNA by HMC-1/PR3 (full circles), HMC-1NEC (open 
triangles), and HMC-1/PR3-S176A cell (stars). Hydrolysis of the 
substrate is inhibited by greater than 95% by 1.85 ktM ctl-PI (open 
circles), but not by 0.1 TIU/ml aprotinin (open squares). Each data 
point represents he mean of duplicates. Shown is a representative 
examples of 5 different experiments. 
target antigens other than PR3. These data indicate that our 
stable expression system for conformationally intact rPR3 
represents a major step towards the development of new 
PR3-specific -ANCA test methods that are more disease spe- 
cific than the current standard I IF method, and more sensitive 
than currently commercially available ELISA methods. 
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